Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD) -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (398)	3/20/2007 2:14:34 PM
From: Ian@SI	Respond to of 588

You and Tuck have convinced me. I'm now out. Besides for the past 2 weeks TD has been politely, and sometimes not so politely, asking me to cover my margin deficit. I've learned how asinine their method of calculating margin requirement for naked puts is. Premium PLUS 30% of the assigned value of the underlying. If out of the money, then that amount is reduced by 30% of the amount it's out of the money. I'd thought it was PREMIUM only for out of the money Puts; and got nailed when IVs went up while prices went down. Even though I had sufficient cash to buy back all my PUTs twice over, they still hastled me to cover. Are other brokers this nasty???

To: dr.praveen who wrote (398)	5/4/2007 9:40:20 AM
From: tuck	Read Replies (1) \| Respond to of 588

[Pharmacokinetics, Tolerability, and Safety of ACP-103 Following Single or Multiple Oral Dose Administration in Healthy Volunteers.] >>J Clin Pharmacol. 2007 May 1; [Epub ahead of print] Pharmacokinetics, Tolerability, and Safety of ACP-103 Following Single or Multiple Oral Dose Administration in Healthy Volunteers. Vanover KE, Robbins-Weilert D, Wilbraham DG, Mant TG, van Kammen DP, Davis RE, Weiner DM. San Diego, California. The pharmacokinetics, safety, and tolerability of ACP-103, a selective serotonin 5-HT2A receptor inverse agonist, were evaluated in 2 double-blind, placebo-controlled, dose escalation studies in healthy male volunteers. Pharmacokinetic sampling was measured up to 216 hours after single oral/nasogastric doses of ACP-103 and after the last dose of once-daily oral administration of ACP-103 for 14 days. Single doses of ACP-103 (20-300 mg) resulted in dose-proportionate mean Cmax values (9-152 ng/mL) and AUC0-infinity (706-10 798 h.ng/mL), and multiple doses (50-150 mg) resulted in dose-proportionate mean Cmax,ss (93-248 ng/mL) and AUC0-infinity,ss (1839-4680 h.ng/mL). The half-life of ACP-103 was approximately 55 hours, with a tmax at 6 hours. ACP-103 was well tolerated at single doses up to and including 300 mg and multiple doses up to 100 mg once daily for 14 days.<< This is obviously not the data you're looking for, but I'm parking it, anyway. Sorry if this is already known to the board, but as you can see, it's a fresh article if not fresh data. Cheers, Tuck